Clinical Trials Browser

Maraviroc × Other hematologic neoplasm × Clear all

NCT05470491 2026-06-03

Trial of Allogeneic Reduced-Intensity, HLA-Haploidentical Allogeneic Hematopoietic Cell Bone Marrow Transplantation Followed by Graft-versus-Host-Disease (GVHD) Prophylaxis With Cyclophosphamide, Bortezomib and Maraviroc for Hematologic Malignancies ...

Phase 1/2 Recruiting

Other hematologic neoplasm

Acquired Immunodeficiency Syndrome, Hematologic Neoplasms

NCT01785810 2021-01-11

Phase II Maraviroc for GVHD Prevention

Phase 2 Completed

37 enrolled 17 charts

Other hematologic neoplasm

Hematologic Neoplasms

NCT02208037 2019-01-23

Novel Approaches for Graft-versus-Host Disease Prevention Compared to Contemporary Controls (BMT CTN 1203)

Phase 2 Completed

279 enrolled 28 charts

Classical hematologyLymphoidMyeloidOther hematologic neoplasm

Anemia, Refractory, with Excess of Blasts, Hodgkin Disease, Lymphoma, Follicular, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Acute, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse, Precursor Cell Lymphoblastic Leukemia-Lymphoma